NC
Neurocompute
AI-powered research intelligence
 Partner With Us →
Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,279 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

Explore Platform → See latest papers
40,279 Papers indexed
1,440 Papers AI scored
40,279 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.
LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-10 10:15 AM
1 Sensitive LC-MS/MS Method for Simultaneous Quantification of Alectinib and Its Major Metabolite M4 in Limited-Volume Human Plasma. Biomedical chromatography : BMC — Nov 10, 2026 2 Patient reimbursement in therapeutic cancer clinical trials: An 18-year multicenter experience. Cancer — Nov 10, 2026 3 Avoid, repair, tolerate: emerging mechanisms of MAP therapy resistance in osteosarcoma. Biological chemistry — Nov 10, 2026 4 Peritoneal metastasis of histone 3 lysine 27-to-methionine-mutant diffuse midline glioma via ventriculoperitoneal shunt: laparoscopic confirmation of occult disease and the need for multimodal liquid biopsy. BMJ case reports — Nov 10, 2026 5 Nanotechnology-enabled drug delivery for retinoblastoma: formulation strategies, ocular targeting and translational perspectives. Nanomedicine (London, England) — Nov 10, 2026 6 Outcomes of Proton Beam Therapy in Infants and Very Young Children. Practical radiation oncology — Nov 10, 2026 7 A "Hot" Sulfur Colloid Clue in a Hypervascular Pediatric Liver Mass: Resolving a Large Focal Nodular Hyperplasia Mimicking Fibrolamellar Hepatocellular Carcinoma. Clinical nuclear medicine — Nov 10, 2026 8 Investigating the Effect of Synbiotic Supplementation on Inflammatory Indices in Critically Ill Septic Children: a Triple Blind Randomized Controlled Trial. Probiotics and antimicrobial proteins — Nov 10, 2026
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40279 results
D
CHD2 Regulates Neuron-Glioma Interactions in Pediatric Glioma.
PMID 38767413 Published: 2024-09-04 Ingested: 2026-08-02 12:02 AM Cancer discovery
AI -
Standard 49.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 21.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

D
Transdifferentiation of Pediatric Pre-B-ALL Into Histiocytic Sarcoma Harboring BRAF and FLT3 Mutations: Durable Remission With MEK Inhibition, Surgery, and Allogeneic Stem Cell Transplantation.
PMID 42527376 Published: 2026-07-29 Ingested: 2026-08-02 12:07 AM Pediatric blood & cancer
AI -
Standard 49.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

D
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer.
PMID 42377814 Published: 2026-08-01 Ingested: 2026-08-02 12:07 AM International journal of clinical oncology
AI -
Standard 49.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

D
Coexistent Leukemia in an Adolescent Boy with Worsening Disseminated TB: Drug Resistance a Clinical Masquerade and Overhype!
PMID 42240766 Published: 2026-06-04 Ingested: 2026-08-02 12:07 AM Indian journal of pediatrics
AI -
Standard 49.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

D
Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.
PMID 42237638 Published: 2026-06-04 Ingested: 2026-08-02 12:07 AM Pediatric blood & cancer
AI -
Standard 49.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

D
Closing the paediatric gap in cancer drug development: a call to industry.
PMID 42215659 Published: 2026-05-29 Ingested: 2026-08-02 12:06 AM Nature reviews. Drug discovery
AI -
Standard 49.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

D
Sooner rather than later: delayed tumour resection and long-term outcome in paediatric NMDAR-antibody encephalitis.
PMID 42049557 Published: 2026-04-20 Ingested: 2026-08-02 12:06 AM European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
AI -
Standard 49.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

D
Alternative versus matched unrelated donor in adolescents and young adults transplanted for acute myeloid leukemia in first complete remission: A report from the SFGM-TC.
PMID 41975071 Published: 2026-04-13 Ingested: 2026-08-02 12:06 AM Bone marrow transplantation
AI -
Standard 49.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

D
Skin and soft tissue infections in pediatric patients with inflammatory bowel disease treated with tumor necrosis factor-α inhibitors.
PMID 41616932 Published: 2026-01-29 Ingested: 2026-08-02 12:06 AM Journal of the American Academy of Dermatology
AI -
Standard 49.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

D
Action for first-line PD-1 inhibitors in paediatric Hodgkin lymphoma.
PMID 41519588 Published: 2026-01-10 Ingested: 2026-08-02 12:12 AM Lancet (London, England)
AI -
Standard 49.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 49.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 20.8; sample size: 20.0; recency: 100.0; abstract quality: 0.0.

Previous
Page 2948 of 3357
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic